Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAtomo Diagnostics Ltd

Atomo Diagnostics Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.012 AUD -0.00 ( 7.69%)
Last update at 2026-11-12T05:10:00Z
VOLUME
8580290
Market Cap
15.34M

Momentum Score

…

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-testing programs; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Atomo Diagnostics develops and manufactures rapid point-of-care and self-administered lateral-flow tests for infectious diseases for clinical and retail channels. Its growth drivers include rising demand for decentralized testing, distribution expansion and scaling manufacturing, and investors may view exposure to the expanding point-of-care market and integrated test designs as attractive.

Key risks include intense competition from larger diagnostics firms, dependence on a small number of contracts, variable pandemic-driven demand and regulatory and execution risk that could pressure revenues or require further funding.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
5.33M
Revenue Per Share
0.01
Gross Profit TTM
1.76M
Debt / Equity
0.05
ROE
-47.86%
Net Debt
-3.34M
ROCE
-72.06%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4.77M -4.97M -6.85M -9.96M -5.71M
Net income -3.51M -4.97M -6.85M -9.96M -5.72M
Selling general administrative - 1.14M 4.06M 4.86M 4.15M
Selling and marketing expenses - 3.58M 4.47M - -
Gross profit -2.43M 1.79M 1.44M 0.67M 4.25M
Reconciled depreciation - 1.58M 1.66M 1.89M 2.00M
Ebit -5.69M -5.84M -7.78M -11.21M -5.69M
Ebitda -4.26M -4.69M -6.12M -9.32M -3.69M
Depreciation and amortization 1.43M 1.14M 1.66M 1.89M 2.00M
Operating income -5.69M -3.81M -7.16M -11.21M -5.69M
Other operating expenses 11.02M 7.60M 11.25M 13.75M 20.81M
Interest expense 0.01M 0.02M 0.01M 0.11M 0.02M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.06M 0.15M 0.01M 0.01M
Net interest income - 0.04M 0.14M 0.06M -0.01M
Income tax expense -1.26M - -0.94M -0.06M 0.02M
Total revenue 5.33M 3.79M 4.09M 2.54M 12.34M
Total operating expenses 3.26M 5.60M 8.77M 11.88M 12.72M
Cost of revenue 7.76M 2.00M 2.65M 1.88M 8.09M
Total other income expense net 0.91M -1.16M -0.63M 1.19M -0.02M
Net income from continuing ops - -4.97M -6.85M -9.96M -5.71M
Net income applicable to common shares - -4.97M -6.85M -9.96M -5.71M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 10.83M 9.28M 11.38M 16.47M 26.62M
Intangible assets 1.22M 1.64M - 3.30M 3.57M
Total liab 3.12M 2.30M 1.29M 1.68M 1.81M
Total stockholder equity 7.71M 6.98M 10.08M 14.79M 24.81M
Deferred long term liab - - - 1.94M 2.20M
Other current liab 0.56M - 0.57M 0.96M 1.00M
Common stock 75.83M - 70.09M 68.04M 68.04M
Capital stock - 71.84M - 68.04M 68.04M
Retained earnings -68.47M -64.95M -60.09M -53.55M -44.03M
Other liab - - - 0.10M 0.09M
Other assets - - 0.00M 1.94M 2.20M
Cash 3.71M 3.22M 3.69M 6.47M 12.97M
Total current liabilities 2.93M 2.17M 1.19M 1.49M 1.53M
Current deferred revenue 1.06M - 0.05M 0.19M -
Net debt -3.34M - -3.60M -6.22M -12.63M
Short term debt 0.26M - 0.08M 0.17M 0.16M
Short long term debt total 0.37M - 0.08M 0.25M 0.34M
Other stockholder equity - - - 0.30M 0.80M
Property plant equipment - - - 2.74M 3.98M
Total current assets 8.90M 6.56M 7.59M 10.43M 19.07M
Net tangible assets - - - 13.43M 23.44M
Net receivables 3.22M 0.63M 2.06M 1.82M 2.68M
Inventory 1.97M 1.65M 1.84M 2.14M 3.42M
Accounts payable 1.05M 0.38M 0.48M 0.18M 0.38M
Accumulated other comprehensive income 0.35M - 0.09M 0.30M 0.80M
Non currrent assets other - - 2.07M - -
Non current assets total 1.92M 2.71M 3.79M 6.04M 7.56M
Capital lease obligations - 0.19M - 0.25M 0.34M
Long term debt total - - - 0.08M 0.18M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.03M -0.02M -0.40M -2.31M
Change to liabilities - - - 0.06M -0.73M
Total cashflows from investing activities -0.04M -0.03M -0.02M -0.40M -2.31M
Net borrowings - - - -0.17M -0.05M
Total cash from financing activities 3.81M 1.46M 1.87M -0.17M 0.02M
Change to operating activities - - - -0.00M 0.03M
Net income -3.51M -4.97M -6.85M -9.96M -5.72M
Change in cash 0.49M -0.47M -2.78M -6.50M -4.98M
Begin period cash flow 3.22M 3.69M 6.47M 12.97M 17.95M
End period cash flow 3.71M 3.22M 3.69M 6.47M 12.97M
Total cash from operating activities -3.37M -1.96M -4.69M -5.85M -3.72M
Issuance of capital stock - 1.65M 2.05M - 0.07M
Depreciation 1.43M 1.58M 1.66M 1.44M 2.00M
Change to inventory -0.32M 0.19M 0.30M 1.28M -0.38M
Change to account receivables -1.62M 0.26M -0.58M 0.82M 1.71M
Sale purchase of stock - - - 0.00M 0.07M
Other cashflows from financing activities -0.24M - -0.18M -0.17M -0.05M
Change to netincome - - - 0.06M 0.27M
Capital expenditures 0.04M 0.03M 0.02M 0.40M 2.31M
Change in working capital -1.47M 0.45M -0.27M 0.07M 0.01M
Stock based compensation - 0.03M 0.04M - -
Other non cash items 0.19M 0.95M 0.74M - 3.72M
Free cash flow -3.40M -1.99M -4.70M -6.25M -6.03M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AT1
Atomo Diagnostics Ltd		 -0.00
7.69%		 0.01 - 84.75 2.22 1.64 1.78 -1.93
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Atomo Diagnostics Ltd

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-testing programs; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

3-5 George Street, Leichhardt, NSW, Australia, 2040

61 2 9099 4750

https://atomodiagnostics.com

Name Title Year Born
Mr. John Michael Kelly Founder, CEO, MD & Director NA
Mr. William Edward Souter BCom, LLB (Adel), IPAA Chief Financial Officer NA
Ms. Chandra Sukumar Chief Operating Officer NA
Mr. Jim P. McMenamy Head of Bus. Devel. & Partnerships of the Americas NA
Ms. Anna Tucker Head of Bus. Devel. & Partnerships of Europe, Middle East and Africa NA
Mr. Tharun Kuppanda Company Sec. NA
Mr. Jim P. McMenamy Head of Business Development & Partnerships of the Americas NA
Ms. Anna Tucker Head of Business Development & Partnerships of Europe, Middle East and Africa NA
Ms. Maria Clemente Company Secretary NA
Mr. Jim P. McMenamy Head of Business Development & Partnerships of the Americas NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…